Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Open-label Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
jRCT2031250237Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of mezagitamab in immune thrombocytopenia (ITP), sponsored by Takeda. Primary endpoints: Number of participants with treatment-emergent adverse events (TEAEs) and serious TEAEs and Number of participants with TEAEs leading to permanent withdrawal of mezagitamab. Started Aug 2025; status: recruiting.
02
Drugs
mezagitamab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on jRCT2031250237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250237.